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Abstract
Background Infection in severe pressure ulcers can lead
to sepsis with a 6-month mortality as high as 68%.
Methods Operative records of 142 consecutive operative
debridements on 60 patients in a dedicated wound healing
inpatient unit were reviewed, from the Wound Electronic
Medical Record, for identiﬁcation of key steps in
debridement technique, mortality, unexpected returns, and
time to discharge following debridement.
Results The mean age of the patients was 73.1 years, and
45% were men. Most wounds (53%) were located on the hip
(ischial or trochanteric); others were on the sacrum (32%)
and the heels (14%). The mean initial wound area prior to
debridement was 14.0 cm
2, and 83% of debridements were
performed on stage IV pressure ulcers. The postoperative
hospital stay averaged 4.1 days. Key steps in the technique
included (1) exposure of areas of undermining by excising
overlyingtissue;(2)removalofcallusfromwoundedges;(3)
removal of all grossly infected tissue; and (4) obtaining a
biopsy of the deep tissue after debridement of all nonviable
or infected tissue for culture and pathology to determine the
presence of infection, ﬁbrosis, and granulation tissue. There
was one death 9 days post-debridement of a sacral ulcer and
one unplanned return to the operating room for bleeding
8 days post-debridement.
Conclusions Operative debridement of pressure ulcers is
safe, despite the medical co-morbidities in patients with
severe pressure ulcers. Proper debridement technique may
prevent sepsis and death in patients with multiple co-
morbid conditions.
Introduction
Pressure ulcers commonly affect bed-bound patients with
acute or chronic illnesses [1]. The prevalence of pressure
ulcers in the United States is as high as 27.7% in long-term
care settings [2]. Hospitalizations directly related to pres-
sure ulcers have increased by 63% over a 10-year period,
and septicemia is the most common admitting diagnosis
[3]. Mortality exceeds 68% in certain settings[4]. Because
pressure ulcers are commonly associated with co-morbid
conditions such as dementia, spinal cord injury, stroke, or
other acute illness in hospitalized patients [3], the true
prevalence may be underestimated. According to the
Center for Medicaid and Medicare Services (CMS), the
average hospital charge per pressure ulcer patient exceeds
$43,000. The cost to acute care hospitals has increased
signiﬁcantly in light of a recent announcement by the CMS
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hospital as a ‘‘never event,’’ and consequently care for
these hospital-acquired stage III or IV pressure ulcers will
no longer be reimbursed [5].
Pressure ulcers are caused by multiple pathogenic
mechanisms, including direct pressure [6, 7] and micro-
circulatory ischemia [8]. Despite a rising incidence of
pressure ulcers in the United States, the molecular mech-
anisms behind their development have not been fully elu-
cidated. Tissue changes in response to pressure may
include structural changes in the dermis and cellular
deformation followed by cytoskeletal and extracellular
matrix alterations [9, 10]. The epidermis of the non-healing
edge of the pressure ulcers, as well as that of venous and
diabetic foot ulcers, shows increased expression of c-myc
and activation of nuclear b-catenin that leads to formation
of thick, hyperproliferative epidermis [11].
When patients present with stage III or IV ulcers,
treatment is directed toward prevention and management of
secondary complications—especially sepsis—and promo-
tion of wound healing. Removal of devitalized tissue is
necessary for wound healing [12], because moist necrotic
tissue provides a medium for infection [13] that triggers an
inﬂammatory response [14] and eventually results in
impaired wound healing [15]. Sharp debridement removes
this source of infection and sepsis [16]. Small or superﬁcial
wounds can be debrided at the bedside, but debridement in
the operating room is often necessary for stage III and IV
ulcers.
Operative debridement to treat pressure ulcers has been
extensively described, with the ﬁrst report of operative
debridement to adequately prepare the wound bed for
healing published in 1950 by Cannon et al. [17]. Since
then, a number of reports have detailed certain aspects of
the surgical technique [18–25], although few have offered a
step-by-step description and subsequent outcomes.
Regardless of whether a pressure ulcer heals subsequently
by myocutaneous ﬂap coverage or by secondary intention,
surgical debridement to remove infection is an integral part
of wound bed preparation.
The indications for the operative procedure include, but
are not limited to, the following:
1. Removal of the source of sepsis, deﬁned as systemic
inﬂammatory response syndrome (SIRS) in the pres-
ence of infection. (Diagnostic criteria for SIRS include
any two of the following: temperature 38 or 36C,
heart rate[90 bpm, respiratory rate C 20 breaths/
min or PaCO2 B 32 mmHg or mechanical ventilation,
and white blood cell count C 12,000/llo rB 4,000/ll
or C 10% band forms [26]).
2. Removal of local infection to decrease bacterial
burden, to reduce the probability of resistance from
antibiotic treatment, and to obtain accurate cultures
[27].
3. Collection of deep cultures taken after debridement
from the tissue left behind to evaluate persistent
infection and requirements for systemic antibiotic
treatment [27].
4. Stimulation of the wound bed to promote healing and
prepare for a skin graft or ﬂap [28].
The purpose of the present study is to describe a tech-
nique for operative debridement of severe pressure ulcers.
This procedure results in low mortality despite the multiple
co-morbidities of pressure ulcer patients.
Materials and methods
Operative reports for 142 consecutive debridements from
60 patients were reviewed. All patients were treated at a
single university-based, tertiary care hospital by a single
surgeon and admitted to a dedicated wound healing inpa-
tient unit from January 2004 to December 2006.
Patient age, gender, wound location, wound area, and
pressure ulcer staging at the time of operative debridement
were abstracted from the Wound Electronic Medical
Record. The number of debridements per wound was cal-
culated. The time to discharge after debridement was cal-
culated per operation. If debridement was performed on the
same wound on subsequent occasions during the same
admission, the time to discharge was calculated from the
day of the ﬁrst debridement. Criteria deﬁning a safe
operation included (1) no unplanned return to the operating
room during hospital stay and (2) no mortality prior to
discharge from the hospital. Descriptive statistics were
tabulated with MS Excel 2007 (Microsoft Corporation,
Redmond, WA). This study was approved by the Institu-
tional Review Board.
Results
Key steps in the operative technique
Prior to operation, the surgeon explored the wound for
undermining, using a swab or gloved ﬁnger (Fig. 1).
Undermining is deﬁned by CMS as the destruction of tissue
or ulceration extending under the skin edges such that the
pressure ulcer measures larger at its base than at the skin
surface [29]. For patients with sacral or ischial pressure
ulcers, a rectal exam was performed, and the area overlying
the rectum was indicated with a marking pen. During
debridement, the perirectal ﬁbrinous tissue may be
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123removed, but deep penetration to the rectal muscle should
be avoided.
The wound was widely prepped in order to capture the
outermost area of undermining. Segments of the overlying
tissue were resected to expose areas of undermining. This
tissue usually includes healthy-appearing skin as well as
the underlying subcutaneous tissue and fascia, and it is
resected in triangular segments, using electrocautery to
minimize bleeding. As Figs. 2 and 3 illustrate, the apex of
the triangle should extend to the outermost circumference
of the area of undermining, and the base of the triangle
should be adjacent to the outer edge of the wound. The
resected area should be restricted to the minimum amount
needed to expose the pockets of undermining and to allow
for debridement of underlying necrotic tissue and full
exposure of the wound bed. This resection will also allow
for deep packing in dressing changes. Although healthy
skin is removed, this skin typically heals faster than tissue
at the base of the wound (Fig. 4).
All necrotic, infected, and nonhealing tissue from the
wound base is debrided using a scalpel, electrocautery,
rongeur, or curette. This may include subcutaneous tissue,
muscle, tendon, and/or bone. Removal of this material is
achieved by grasping the tissue with an Alice clamp or
other suitable clamp and layer-by-layer excision with a
scalpel. Caution should be taken because nonviable tissue,
including necrotic muscle, can bleed. Soft bone usually is
an indication of osteomyelitis and should be debrided with
a rongeur. Adequate debridement is deﬁned by the absence
of infection and ﬁbrosis in the wound bed, as determined
by culture and pathology.
Routine pathology
Routine hematoxylin and eosin (H&E) staining of
debridement specimens is helpful in determining the
appropriate depth of debridement i.e. all necrotic, infected,
and nonhealing tissue is debrided. Figure 5 illustrates the
pathology for the wound debridement shown. The area of
skin over undermining contains granulation tissue (G),
which contains multiple inﬂammatory cells and newly
formed blood vessels. However, deep to the granulation
tissue is an area of ﬁbrosis (F), which contains acellular
woven strands of collagen. This scar tissue indicates that
further debridement is needed to reach healthy granulation
tissue. Skeletal muscle (M) is often encountered (as shown
in Fig. 5b), surrounded by areas of ﬁbrosis (F) and gran-
ulation tissue (G). The goal is to remove all infection and
Fig. 1 Exploration of the wound for undermining can be performed
with a gloved ﬁnger or a sterile cotton swab, as depicted here
Fig. 2 Outline of triangular segment of undermining
Fig. 3 Triangular segment of skin covering undermining removed
Fig. 4 Triangular segment of skin removed and sent to pathology
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usually involves bone in stage IV pressure ulcers. As
shown in Fig. 5c, viable bone (B) is evident, as indicated
by the multiple nuclei (encircled) surrounded by granula-
tion tissue (G), and there is no evidence of infection, i.e.
osteomyelitis. Occasionally, ﬁbrotic bone is encountered,
and this ﬁnding may have potentially different implications
for healing than osteomyelitis.
After a deep tissue specimen following debridement has
been sent for pathology and culture, hemostasis is achieved.
Injuries to blood vessels are repaired with absorbable
sutures in a ﬁgure-of-eight or locked running technique.
Manual pressure stops most capillary bleeding. Further
hemostasis can be achieved by a variety of methods
including electrocautery, Gelfoam thrombin (Pﬁzer, New
York, NY) [30, 31], or Surgicel (Johnson & Johnson, Pis-
cataway, NJ) [32]. Our preference is Floseal (Baxter,
Deerﬁeld, IL) [31] (Figs. 6, 7). The wound is then packed
with a microﬁbrillar collagen [33] such as Instat (Johnson &
Johnson, Piscataway, NJ) (Fig. 7), after which sterile gauze
and a Tegaderm dressing (3 M, St Paul, MN) are applied.
Postoperative wound management
Dressings are left in place for up to 5 days after surgery
depending on the amount of serous or serosanguinous
drainage. Once the postoperative dressing is removed,
topical dressings such as Silvadene [34], collagenase
(Worthington Biochemical Corporation, Lakewood, NJ)
[35], or Iodosorb (Smith & Nephew, Hull, UK) [36] will
provide a moist wound environment for healing [37].
Vacuum-assisted closure (VAC) therapy (V.A.C.; KCI,
San Antonio, TX) can be considered [38] and employed in
accordance to published guidelines [39]. Pressure ulcer
patients require pressure-relief mattresses. Patients with
heel ulcers require ofﬂoading devices such as heel lifts or
MultiPodus boots (RCAI, St. Petersburg, FL). For contin-
uing wound treatment, patients beneﬁt from either home
care (e.g., nurses) or nursing home services [37].
Wound characteristics and operative safety
This study reviews 142 debridements performed on 60
patients (45% of them men). The initial ulcer area prior to
Fig. 5 a Low-power view of
excised skin over area of
undermining. The superior
black arrow indicates
hyperkeratotic and thickened
skin, and the inferior arrow
indicates the ulcer bed. A layer
of granulation tissue (G) was
present as deeper ﬁbrosis (F). b
Pressure ulcer debridement
often may extend and require
removal of scarred muscle (M).
F regions of ﬁbrosis; G an area
of granulation tissue. c A
fragment of viable bone (B) as
evidenced by nucleated
osteocytes (black circle) and
adjacent ﬁbrosis (F)
Fig. 6 Application of Floseal to achieve hemostasis
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123debridement was 14 ± 18.9 cm
2. Because patients often
had multiple wounds, operative debridement was per-
formed on 77 stage IV, 6 stage III, 4 stage II, and 37
unstageable ulcers. Results are summarized in Table 1.
There was one postoperative death in this series. A 79-
year-old man died 9 days after undergoing debridement of
a sacral ulcer. There was also one unplanned return to the
operating room for bleeding 8 days post-debridement of a
sacral ulcer in an 82-year-old woman.
Discussion
Patients with stage III and IV pressure ulcers comprise a
population with multiple co-morbidities and high mortality,
often requiring multiple hospital admissions [40, 41]. In
this report we document the effectiveness of operative
debridement—even in patients with severe pressure
ulcers—showing that it can be performed safely and result
in low mortality rates.
Most of the patients in this study required multiple de-
bridements because of the severity of their ulcers. In this
group, we observed a large incidence of undermining
(Fig. 1). Resection of undermined tissue is advocated
because of the underlying pathology that often accompa-
nies this ﬁnding. As indicated in Fig. 6a, which illustrates
the H&E staining of the skin over the specimen shown in
Fig. 4, ﬁbrosis (F) is visible deep to the granulation tissue.
The granulation tissue (G) of the ulcer bed is indicated by
the lower black arrow, and it extends to the area underneath
the acanthotic and hyperkeratotic tissue epithelium, as
indicated by the top arrow of undermining. Hyperkeratosis
is indicative of abnormal keratinocyte migration and dif-
ferentiation [42, 43], and in pressure ulcers, hyperkeratotic
epidermis may prevent the ulcer from healing and should
be resected [11].
When a wound is debrided for the ﬁrst time, the extent
of debridement depends on the gross appearance of the
tissue. If the patient has undergone prior debridements,
pathology results from previous surgeries will be crucial in
identifying areas of remaining nonviable tissue or scar, and
thereby determining the extent of subsequent debride-
ments. The pathology report will conﬁrm the viability of
remaining tissue—e.g., if it contains well-vascularized
granulation tissue free of infection and scar. Cultures taken
from the same area will reveal any remaining bacteria.
Exposed bone should always be sent for culture to assist in
the diagnosis and treatment of osteomyelitis.
Because of the high incidence of medical co-morbidities
in patients with pressure ulcers, patients may be coagulo-
pathic from medication, chronic diseases, or sepsis.
Patients at risk for cardiac ischemia should be treated
perioperatively with beta-blockers, according to the
American College of Cardiology/American Heart Associ-
ation guidelines [44]. Patients receiving antiplatelet agents
should continue these medications and not compromise
their therapeutic or prophylactic effects. If surgery is per-
formed while the patient is being anticoagulated in order to
remove a source of sepsis, a limited debridement may be
done, with the intention to return to the operating room for
further serial procedures. The surgeon should be prepared
to use multiple hemostatic agents (Figs. 6, 7) in addition to
judicious cauterization and manual pressure.
There is extensive literature on deﬁnitive closure of
pressure ulcers with ﬂaps, although most acutely ill patients
requiring debridement are not candidates for myocutaneous
ﬂaps. The purpose of the debridement technique described
here is to remove sources of sepsis and to stimulate wound
healing.
Although operative mortality was low in this study
(2%), long-term mortality may be as high as 68% following
debridement [45]. Hospitalized patients with severe pres-
sure ulcers generally have multiple medical co-morbidities,
Table 1 Descriptive table for surgical debridement of pressure ulcers
Percentage of total
Wound characteristics (n = 91)
Hip (ischial ? trochanteric) 53%
Sacrum 32%
Heel 14%
Other 1%
Debridement characteristics (n = 142)
Mean age at debridement (years) 73.1 ± 17
Mean initial stage at debridement 3.6 ± 0.7
Percentage of stage IV debrided 83%
Mean initial wound area ± SD (cm
2) 14.0 ± 18.9
Mean days to discharge after debridement 4.1 ± 4.5
Fig. 7 Application of collagen to achieve hemostasis
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[4, 46]. In patients with heel ulcers, ischemia should be
assessed prior to operation by obtaining an ankle-brachial
index and pulse volume recording [47]. If ischemia is
present, surgical debridement may be necessary to remove
actively infected tissue that is a potential source of sepsis;
however, elective procedures should be deferred until after
revascularization has been achieved.
Acute illness from systemic effects of infection is
common. As in all surgeries, preoperative assessment
should focus on optimizing the patient for the procedure.
Patients are frequently dehydrated and require ﬂuid resus-
citation and close monitoring of ﬂuid status by measure-
ment of ﬂuid intake and output, Foley catheterization,
calculation of fractional excretion of sodium, and mea-
surement of central venous pressure.
The primary physician should initiate discussions with
the patient about palliative care and surgical care, with
surgical referral completed only after the decision to
operate has been made. The surgeon can then assess the
nature, risks, and beneﬁts of operative debridement, and
can discuss in detail with the patient. Once debridement
has been performed, intensive, long-term follow-up is
required to monitor healing rate, manage local wound care,
detect wound infections early, and plan for repeat
debridement if necessary. Close coordination between
inpatient and outpatient management is crucial.
The surgical technique described here is safe for hos-
pitalized patients with severe pressure ulcers. Further study
would be of interest to measure outcomes such as healing
rates and mortality, particularly in the diabetic and elderly
populations. Moreover, randomized controlled trials cor-
relating the histopathology and culture of debridement with
outcomes are also warranted.
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